title: Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.
abstract: Colonic diverticulosis imposes a significant burden on industrialized societies. The current accepted causes of diverticula formation include low fiber content in the western diet with decreased intestinal content and size of the lumen, leading to the transmission of muscular contraction pressure to the wall of the colon, inducing the formation of diverticula usually at the weakest point of the wall where penetration of the blood vessels occurs. Approximately 20 % of the patients with colonic diverticulosis develop abdominal symptoms (i.e., abdominal pain and discomfort, bloating, constipation, and diarrhea), a condition which is defined as symptomatic uncomplicated diverticular disease (SUDD). The pathogenesis of SUDD symptoms remains uncertain and even less is known about how to adequately manage bowel symptoms. Recently, low-grade inflammation, altered intestinal microbiota, visceral hypersensitivity, and abnormal colonic motility have been identified as factors leading to symptom development, thus changing and improving the therapeutic approach. In this review, a comprehensive search of the literature regarding on SUDD pathogenetic hypotheses and pharmacological strategies was carried out. The pathogenesis of SUDD, although not completely clarified, seems to be related to an interaction between colonic microbiota alterations, and immune, enteric nerve, and muscular system dysfunction (Cuomo et al. in United Eur Gastroenterol J 2:413-442, 2014). Greater understanding of the inflammatory pathways and gut microbiota composition in subjects affected by SUDD has increased therapeutic options, including the use of gut-directed antibiotics, mesalazine, and probiotics (Bianchi et al. in Aliment Pharmacol Ther 33:902-910, 2011; Comparato et al. in Dig Dis Sci 52:2934-2941, 2007; Tursi et al. in Aliment Pharmacol Ther 38:741-751, 2013); however, more research is necessary to validate the safety, effectiveness, and cost-effectiveness of these interventions.
authors.affiliation: Department of Medical and Surgical Science, Policlinico S.Orsola, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. elescaio@gmail.com.
authors.forename: Eleonora
authors.initials: E
authors.lastname: Scaioli
authors.affiliation: Department of Medical and Surgical Science, Policlinico S.Orsola, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. antonio.colecchia@aosp.bo.it.
authors.forename: Antonio
authors.initials: A
authors.lastname: Colecchia
authors.affiliation: Department of Medical and Surgical Science, Policlinico S.Orsola, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. giovannimarasco89@gmail.com.
authors.forename: Giovanni
authors.initials: G
authors.lastname: Marasco
authors.affiliation: Department of Medical and Surgical Science, Policlinico S.Orsola, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. ramona_schiumerini@libero.it.
authors.forename: Ramona
authors.initials: R
authors.lastname: Schiumerini
authors.affiliation: Department of Medical and Surgical Science, Policlinico S.Orsola, University of Bologna, Via Massarenti 9, 40138, Bologna, Italy. davide.festi@unibo.it.
authors.forename: Davide
authors.initials: D
authors.lastname: Festi
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D004043:Dietary Fiber / Q000627:therapeutic use*; D004239:Diverticulitis, Colonic / Q000188:drug therapy* / Q000503:physiopathology; D000069196:Gastrointestinal Microbiome; D005769:Gastrointestinal Motility; D006801:Humans; D006941:Hyperesthesia / Q000503:physiopathology; D007249:Inflammation; D019804:Mesalamine / Q000627:therapeutic use*; D019936:Probiotics / Q000627:therapeutic use*
chemical_list: D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D004043:Dietary Fiber; D019804:Mesalamine
keywords: Diverticular disease; Gut microbiota; Low-grade inflammation; Mesalazine; Probiotics